Blockade of IL-6 with tocilizumab and STAT3 knockdown attenuated CD44+ sphere formation and tumor growth of patient-derived HCC as well as breast xenografts (Wan et al., 2014; Wang et al., 2018a). This evidence concerns the gene CD44 and hepatocellular carcinoma.